Topical delivery for the treatment of psoriasis

Bibliography

• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, Association of patient reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57:963-71
   PubMed Web of Science ®Google Scholar
• Campalani E, Barker JNWN. The clinical genetics of psoriasis. Curr Genomics 2005;6:51-60
   Web of Science ®Google Scholar
• Wolf N, Quaranta M, Prescott NJ, Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-16
   PubMed Web of Science ®Google Scholar
• Maurer TA. Dermatologic manifestations of HIV infection. Top HIV Med 2005;13(5):149-54
   PubMedGoogle Scholar
• Gelfand JM, Shin DB, Neimann AL, The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41
   PubMed Web of Science ®Google Scholar
• Su Y-H, Fang J-Y. Drug delivery and formulations for topical treatment of psoriasis. Exp Opin Drug Deliv 2008;5:235-49
   PubMed Web of Science ®Google Scholar
• Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001;76:943-9
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M, German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:5-70
   Web of Science ®Google Scholar
• Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol 1998;138:293-6
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;22:866-73
   Google Scholar
• Yao Y, Richman L, Morehouse C, Type I interferon: potential therapeutic target for psoriasis? PLoS One 2008;3(7):e2737. [Erratum, PLoS One 2009;4(3)]
   PubMedGoogle Scholar
• Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009;84(4 Suppl):14-24
   PubMed Web of Science ®Google Scholar
• Christensen TE, Callis KP, Papenfuss J, Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol 2006;126:2397-403
   PubMed Web of Science ®Google Scholar
• Bagel J. Topical therapies for the treatment of plaque psoriasis. Cutis 2009;84(4 Suppl):3-13
   PubMed Web of Science ®Google Scholar
• Horn EJ, Domm S, Katz HI, Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol 2010;24:119-24
   PubMed Web of Science ®Google Scholar
• Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders-a clinical update. Int J Clin Pract 2006;60:85-92
   PubMed Web of Science ®Google Scholar
• Prakash A, Benfield P. Topical Mometasone: a Review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998;55:145-63
   PubMed Web of Science ®Google Scholar
• Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol 2009;10:397-406
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003;7:185-92
   PubMed Web of Science ®Google Scholar
• Huang X, Tanojo H, Lenn J, A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005;53(1 Suppl 1):S26-38
   PubMed Web of Science ®Google Scholar
• Mraz S, Leonardi C, Colon LE, Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis. J Dermatolog Treat 2008;19:354-9
   PubMed Web of Science ®Google Scholar
• Jarratt M, Breneman D, Gottlieb AB, Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004;3:367-73
   PubMedGoogle Scholar
• Rivera AM, Hsu S. Topical halobetasol propionate in the treatment of plaque psoriasis: a review. Am J Clin Dermatol 2005;6:311-16
   PubMed Web of Science ®Google Scholar
• Bernhard J, Whitmore C, Guzzo C, Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol 1991;25:1170-4
   PubMed Web of Science ®Google Scholar
• Goldberg B, Hartdegen R, Presbury D, A double blind multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic localized plaque psoriasis. J Am Acad Dermatol 1991;25:1145-8
   PubMed Web of Science ®Google Scholar
• Mensing H, Korsukewitz G, Yawalkar S. A double blind multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol 1991;25:1166-9
   PubMed Web of Science ®Google Scholar
• Blum G, Yawalkar S. A comparative multicenter double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic localized plaque psoriasis. J Am Acad Dermatol 1991;25:1153-6
   PubMed Web of Science ®Google Scholar
• Saraceno R, Gramiccia T, Frascione P, Calcipotriene/betamethasone in the treatment of psoriasis: a review article. Expert Opin Pharmacother 2009;10:2357-65
   PubMed Web of Science ®Google Scholar
• Fresta M, Puglisi G. Corticosteroid dermal delivery with skin lipid liposomes. J Control Release 1997;44:141-51
   Web of Science ®Google Scholar
• Korting HC, Zienicke H, Schäfer-Korting M, Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 1990;39:349-51
   PubMed Web of Science ®Google Scholar
• Feldman SR, Ravis SM, Fleischer AB, Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001;5:386-9
   PubMed Web of Science ®Google Scholar
• Stein LF, Sherr A, Solodkina G, Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001;5:303-7
   PubMed Web of Science ®Google Scholar
• Franz TJ, Parsell DA, Halualani RM, Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628-32
   PubMed Web of Science ®Google Scholar
• Muller K, Bendtzen K. 1,25-dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc 1996;1:68-71
   PubMedGoogle Scholar
• Tanghetti EA. The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol 2009;8(8 Suppl):s4-8
   PubMed Web of Science ®Google Scholar
• Barker JN, Ashton RE, Marks R, Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo controlled, double-blind, dose finding study with active comparator. Br J Dermatol 1999;141:274-8
   PubMed Web of Science ®Google Scholar
• Staberg B, Roed-Petersen J, Menne T. Efficacy of topical treatment in psoriasis with MC903, a new vitamin D analogue. Acta Derm Venereol 1989;69:147-50
   PubMed Web of Science ®Google Scholar
• Klaber MR, Hutchinson PE, Pedvis-Leftick A, Comparative effects of calcipotriol solution (50 micograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994;131:678-83
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Cameli N, Calcipotriol ointment in nail psoriasis: a controlled double blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998;139:655-9
   PubMed Web of Science ®Google Scholar
• Kaur I, Saraswat A, Kumar B. Comparison of calcipotriol and coal tar in conjunction with sun exposure in chronic plaque psoriasis: a pilot study. J Dermatol 2001;28:448-50
   PubMed Web of Science ®Google Scholar
• Boyrke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in treatment of psoriasis vulgaris. Clin Exp Dermatol 1993;18:504-6
   PubMed Web of Science ®Google Scholar
• Lehmann B. Role of the vitamin D3 pathway in healthy and diseased skin-facts, contradictions and hypotheses. Exp Dermatol 2009;18:97-108
   PubMed Web of Science ®Google Scholar
• Calcitriol (Vectical) for mild to moderate plaque psoriasis. Med Lett Drugs Ther 2009;51(1320):70-1
   PubMed Web of Science ®Google Scholar
• Kircik L. Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis. J Drugs Dermatol 2009;8(8 Suppl):s9-16
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Menter A, Weiss J, Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007;6:428-35
   PubMedGoogle Scholar
• Harrison PV. Topical tacalcitol treatment for psoriasis. Hosp Med 2000;61:402-5
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Berth-Jones J, Griffiths CE, Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002;146:414-22
   PubMed Web of Science ®Google Scholar
• Lambert J, Trompke C. Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice. Dermatology 2002;204:321-4
   PubMed Web of Science ®Google Scholar
• Syuto T, Ishibuchi H, Sogabe Y, Efficacy of high-concentration tacalcitol ointment in psoriasis vulgaris after changing from other high-concentration vitamin D3 ointments. Dermatol Online J 2008;14:2
   PubMedGoogle Scholar
• van de Kerkhof PC. Update on retinoid therapy of psoriasis in an update on the use of retinoids in dermatology. Dermatol Ther 2006;19:252-63
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin 2004;22:467-76
   PubMed Web of Science ®Google Scholar
• Linden KG, Weinstein GD. Psoriasis: current perspectives with emphasis on treatment. Am J Med 1999;107:595-605
   PubMed Web of Science ®Google Scholar
• Veraldi S, Schianchi R. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2003;206:347-8
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999;37:273-87
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ast E, Callen JP, Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-11
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Krueger GG, Lowe NJ, Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JY, Krueger GG, Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48:760-7
   PubMed Web of Science ®Google Scholar
• Tzung TY, Wu JC, Hsu NJ, Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Acta Derm Venereol 2005;85:236-9
   PubMed Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37
   PubMed Web of Science ®Google Scholar
• Chaterjee DJ, Li WY, Koda RT. Effect of vehicles and penetration enhancers on in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res 1997;14:1058-65
   PubMed Web of Science ®Google Scholar
• Vemulapalli V, Banga AK, Friden PM. Optimization of iontophoretic parameters for the transdermal delivery of methotrexate. Drug Deliv 2008;15:437-42
   PubMed Web of Science ®Google Scholar
• Alvarez-Fifigueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001;215:57-65
   PubMedGoogle Scholar
• Wong TW, Chen CH, Huang CC, Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. J Control Release 2006;110:557-65
   PubMed Web of Science ®Google Scholar
• Vemulapalli V, Yang Y, Friden PM, Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J Pharm Pharmacol 2008;60:27-33
   PubMed Web of Science ®Google Scholar
• Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007;215(Suppl 1):45-54
   PubMedGoogle Scholar
• Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol 2005;53(2 Suppl 2):S165-70
   PubMed Web of Science ®Google Scholar
• Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E, Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006;5:334-6
   PubMedGoogle Scholar
• Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003;13:471-3
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg 2008;12:230-4
   PubMed Web of Science ®Google Scholar
• Freeman AK, Linowski GJ, Brady C, Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564-8
   PubMed Web of Science ®Google Scholar
• Fabroni C, Lotti T. Pimecrolimus in dermatology. G Ital Dermatol Venereol 2009;144:321-5
   PubMed Web of Science ®Google Scholar
• Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin Pharmacother 2006;7:1967-75
   PubMed Web of Science ®Google Scholar
• Gribetz C, Ling M, Lebwohl M, Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-8
   PubMed Web of Science ®Google Scholar
• Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm. Allergy Drug Targets 2007;6:17-26
   PubMedGoogle Scholar
• Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009;10:1236-42
   PubMed Web of Science ®Google Scholar
• Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005;53(1 Suppl 1):S17-25
   PubMed Web of Science ®Google Scholar
• Clareus BW, Houwing R, Sindrup JH, Wigchert S. The DESIRE study – psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice. Eur J Dermatol 2009;19:581-5
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B, Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
   PubMed Web of Science ®Google Scholar
• Douglas WS, Poulin Y, Decroix J, A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-5
   PubMed Web of Science ®Google Scholar
• Guenther LC. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol). Skin Therapy Lett 2009;14:1-4
   PubMedGoogle Scholar
• De Jong EMGJ, Mork NJ, Seijger MM, The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo controlled randomized trial. Br J Dermatol 2003;148:318-25
   PubMed Web of Science ®Google Scholar
• Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002;46:907-13
   PubMed Web of Science ®Google Scholar
• Nguyen T, Gattu S, Pugashetti R, Koo J. Practice of phototherapy in the treatment of moderate-to-severe psoriasis. Curr Probl Dermatol 2009;38:59-78
   PubMedGoogle Scholar
• Gupta AK, Ryder JE. Photodynamic therapy and topical aminolevulinic acid: an overview. Am J Clin Dermatol 2003;4:699-708
   PubMed Web of Science ®Google Scholar
• US FDA. Topical Dermatological Corticosteroids: In Vivo Bioequivalence. Center for Drug Evaluation and Research, June 1995
   Google Scholar
• Shah VP, Flynn GL, Yacobi A, Bioequivalence of topical dermatological dosage forms- methods of evaluation of bioequivalence. Pharm Res 1998;15:167-71
   PubMed Web of Science ®Google Scholar
• US FDA. Guidance for Industry: topical dermatological drug product NDAs and ANDAs – in vivo bioavilability, bioequivalence, in vitro release, and associated studies. Draft Guidance. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1998
   Google Scholar
• US FDA. Guidance for industry on special protocol assessment; availability. Fed Reg 2002;67:35122
   Google Scholar
• N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm Res 2008;25:1621-30
   PubMed Web of Science ®Google Scholar
• Pershing LK, Nelson JL, Corlett JL, Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol 2003;48:740-51
   PubMed Web of Science ®Google Scholar
• Alberti I, Kalia YN, Naik A, Assessment and prediction of the cutaneous bioavailability of topical terbinafine in vivo. Pharm Res 2001;18:1472-5
   PubMed Web of Science ®Google Scholar
• Reddy MB, Stinchcomb AL, Guy RH, Bunge AL. Determining dermal absorption parameters in vivo from tape stripping data. Pharm Res 2002;19:292-7
   PubMed Web of Science ®Google Scholar
• N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res 2009;26:316-28
   PubMed Web of Science ®Google Scholar
• Gschwind H-P, Waldmeier F, Zollinger M, Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro. Eur J Pharm Sci 2008;33:9-19
   PubMed Web of Science ®Google Scholar
• McCarty A, Feldman S. Study of patient preferences for ointment, cream and foam formulations. J Am Acad Derm 2004;50:P150
   PubMed Web of Science ®Google Scholar
• Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit 2008;14:166-74
   Web of Science ®Google Scholar
• Fang Y-P, Huang Y-B, Wu P-C, Tsai Y-H. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm 2009;73:391-8
   PubMed Web of Science ®Google Scholar